Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.

@article{Chittick2006PharmacokineticsOT,
  title={Pharmacokinetics of tenofovir disoproxil fumarate and ritonavir-boosted saquinavir mesylate administered alone or in combination at steady state.},
  author={Gregory E Chittick and Jian Zong and M. Robert Blum and Jeffrey J. Sorbel and John A Begley and Nathalie Adda and Brian P. Kearney},
  journal={Antimicrobial agents and chemotherapy},
  year={2006},
  volume={50 4},
  pages={1304-10}
}
A phase I study was conducted to formally evaluate the steady-state pharmacokinetics (PK) of tenofovir disoproxil fumarate (TDF) and ritonavir (RTV)-boosted saquinavir mesylate (SQV) when coadministered in healthy volunteers. Forty subjects received multiple doses of TDF (300 mg, once daily) and SQV/RTV (1,000 mg/100 mg, twice daily) alone and together under steady-state conditions in an open-label, fixed sequence design. Blood samples for tenofovir (TFV) and SQV/RTV PK were drawn over… CONTINUE READING